Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
Nicholas Giustini, Lyudmila Bazhenova UCSD Moores Cancer Center, Department of Hematology and Oncology, 3855 Health Sciences Drive MC #0987, La Jolla, CA, 92093-0829, USACorrespondence: Nicholas Giustini 3855 Health Sciences Drive #0829, La Jolla, CA, 92093-0829 Email ngiustini@health.ucsd.eduAbstra...
Saved in:
Main Authors: | Giustini N, Bazhenova L |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/d1a3a4b3ebf44cf6bfd02cde9b7868d4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
by: Vicky Mai, et al.
Published: (2021) -
Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression
by: Sun Butong, et al.
Published: (2021) -
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
by: Alberto Bongiovanni, et al.
Published: (2021) -
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer
by: Huiqiu ZHANG, et al.
Published: (2021) -
Identification of circRNA_001846 as putative non–small cell lung cancer biomarker
by: Fan Yang, et al.
Published: (2021)